X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1702) 1702
Publication (226) 226
Newsletter (147) 147
Book Review (32) 32
Conference Proceeding (20) 20
Newspaper Article (16) 16
Book Chapter (15) 15
Magazine Article (4) 4
Dissertation (2) 2
Reference (2) 2
Transcript (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
nilotinib (1738) 1738
index medicus (960) 960
humans (886) 886
imatinib (869) 869
dasatinib (842) 842
chronic myeloid leukemia (760) 760
oncology (612) 612
hematology (507) 507
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (504) 504
chronic myelogenous leukemia (494) 494
imatinib mesylate (430) 430
chronic myeloid-leukemia (400) 400
male (377) 377
protein kinase inhibitors - therapeutic use (354) 354
female (342) 342
leukemia (342) 342
pyrimidines - therapeutic use (334) 334
tyrosine (322) 322
bcr-abl (315) 315
middle aged (311) 311
tyrosine kinase inhibitors (310) 310
antineoplastic agents (297) 297
antineoplastic agents - therapeutic use (297) 297
cancer (295) 295
antimitotic agents (288) 288
tyrosine kinase inhibitor (273) 273
adult (272) 272
research (271) 271
aged (259) 259
care and treatment (254) 254
cml (245) 245
hemic and lymphatic diseases (229) 229
protein-tyrosine kinases - antagonists & inhibitors (229) 229
benzamides (228) 228
follow-up (218) 218
treatment outcome (213) 213
therapy (211) 211
piperazines - therapeutic use (204) 204
pharmacology & pharmacy (192) 192
analysis (187) 187
drug therapy (185) 185
pyrimidines - pharmacology (184) 184
animals (166) 166
protein kinase inhibitors - pharmacology (159) 159
mutation (152) 152
pyrimidines - adverse effects (152) 152
chronic-phase (149) 149
leukemia, myelogenous, chronic, bcr-abl positive - genetics (147) 147
resistance (147) 147
fusion proteins, bcr-abl - genetics (142) 142
drug resistance, neoplasm (141) 141
pyrimidines - administration & dosage (135) 135
medicine & public health (134) 134
kinases (133) 133
dosage and administration (128) 128
aged, 80 and over (127) 127
phenols (122) 122
young adult (122) 122
patients (120) 120
health aspects (118) 118
antineoplastic agents - adverse effects (117) 117
protein kinase inhibitors - adverse effects (117) 117
fusion proteins, bcr-abl - antagonists & inhibitors (114) 114
antineoplastic agents - pharmacology (111) 111
hematology, oncology and palliative medicine (111) 111
imatinib-resistant (110) 110
bosutinib (106) 106
piperazines - pharmacology (105) 105
protein-tyrosine kinase (105) 105
thiazoles - therapeutic use (104) 104
leukemia, myelogenous, chronic, bcr-abl positive - pathology (102) 102
protein kinase inhibitors - administration & dosage (100) 100
adolescent (97) 97
genetic aspects (96) 96
article (92) 92
tyrosine kinase (90) 90
cytogenetic responses (87) 87
oncology, experimental (87) 87
complications and side effects (86) 86
antineoplastic agents - administration & dosage (85) 85
myeloid leukemia (84) 84
survival (84) 84
abridged index medicus (82) 82
drug resistance (79) 79
mesylate (79) 79
leukemia, myeloid, chronic-phase - drug therapy (77) 77
diagnosed chronic-phase (76) 76
medicine (76) 76
mice (75) 75
stem cells (75) 75
prognosis (74) 74
patients receiving imatinib (73) 73
proteins (73) 73
philadelphia chromosome (72) 72
drug resistance, neoplasm - genetics (71) 71
molecular response (71) 71
risk factors (70) 70
chronic myeloid leukaemia (69) 69
patient outcomes (69) 69
philadelphia-chromosome (69) 69
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1786) 1786
French (23) 23
Polish (23) 23
Russian (18) 18
German (11) 11
Czech (8) 8
Japanese (6) 6
Korean (5) 5
Spanish (4) 4
Turkish (4) 4
Hungarian (3) 3
Portuguese (3) 3
Slovak (1) 1
Slovenian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Toxicology, ISSN 0300-483X, 10/2019, p. 152303
Journal Article
Hospital Pharmacy, ISSN 0018-5787, 09/2014, Volume 49, Issue 8, pp. 689 - 691
Journal Article
Annals of Allergy, Asthma & Immunology, ISSN 1081-1206, 08/2019, Volume 123, Issue 2, pp. 216 - 217
Journal Article
Hong Kong medical journal = Xianggang yi xue za zhi, ISSN 1024-2708, 02/2019, Volume 25, Issue 1, pp. 74 - 75
Journal Article
Recent Results in Cancer Research, ISSN 0080-0015, 2018, Volume 212, pp. 69 - 85
With imatinib still being linked to the breakthrough in CML therapy and probably being the most prescribed drug, second-generation TKIs are increasingly... 
Nilotinib | CML | TKI
Journal Article
Cukurova Medical Journal (Çukurova Üniversitesi Tıp Fakültesi Dergisi), ISSN 0250-5150, 09/2017, Volume 42, Issue 3, pp. 602 - 603
Journal Article
Indian Journal of Medical Research, ISSN 0971-5916, 05/2019, Volume 149, Issue 5
Journal Article
Cancer, ISSN 0008-543X, 02/2011, Volume 117, Issue 4, pp. 688 - 697
Tyrosine kinase inhibitor (TKI) treatment targeting breakpoint cluster region‐Abelson murine leukemia virus, the cause of chronic myeloid leukemia (CML), has... 
imatinib | dasatinib | tyrosine kinase inhibitor | nilotinib | intolerance
Journal Article
Neuroscience, ISSN 0306-4522, 2015, Volume 304, pp. 316 - 327
Highlights • Pre-plaque changes of systemic inflammatory markers. • Early communication between brain and blood immunity. • TKIs in early pre-plaque Aβ stages... 
Neurology | plaque | inflammation | nilotinib | CX3CL1 | bosutinib
Journal Article
Oncotarget, ISSN 1949-2553, 2018, Volume 9, Issue 18, pp. 14219 - 14227
Second-generation tyrosine kinase inhibitors (2G-TKIs) dasatinib and nilotinib produced historical rates of about 50% complete cytogenetic response (CCyR) and... 
Nilotinib | Dasatinib | Second-line | CML | Outcomes
Journal Article
Journal Article
LEUKEMIA RESEARCH, ISSN 0145-2126, 10/2016, Volume 49, pp. S1 - S2
Conference Proceeding
Drug and Chemical Toxicology, ISSN 0148-0545, 2018, pp. 1 - 11
Tyrosine kinase inhibitors (TKIs) have been developed as therapeutic compounds for inhibiting the progression of liver fibrosis. In the present study, the... 
Nilotinib | carbon tetrachloride | losartan | liver cirrhosis
Journal Article
Clinical Management Issues, ISSN 1973-4832, 10/2015, Volume 7, Issue 1S, pp. 9 - 12
The possible cardiotoxicity of tyrosine kinase inhibitors (TKIs) is a topic of extreme interest because in the clinical practice it is frequent the management... 
Nilotinib | Cardiotoxicity | Coronary artery disease Keywords: Nilotinib | Coronary artery disease
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 04/2019, Volume 60, Issue 5, pp. 1116 - 1125
For patients with chronic myeloid leukemia in chronic phase with sustained deep molecular responses on long-term tyrosine kinase inhibitor (TKI) therapy,... 
clinical trial | imatinib | Chronic myeloid leukemia | tyrosine kinase inhibitor | nilotinib | treatment-free remission | MAJOR MOLECULAR RESPONSE | CHRONIC MYELOID-LEUKEMIA | CESSATION | TREATMENT DISCONTINUATION | RELAPSE | THERAPY | ONCOLOGY | HEMATOLOGY | INTERIM ANALYSIS | CML PATIENTS | FRONTLINE NILOTINIB
Journal Article
Biological & Pharmaceutical Bulletin, ISSN 0918-6158, 2015, Volume 38, Issue 5, pp. 645 - 654
Imatinib, nilotinib, and dasatinib are tyrosine kinase inhibitors (TKIs) that have become first-line treatments for Philadelphia chromosome-positive chronic... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.